PMID- 34619181 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220719 IS - 1097-6825 (Electronic) IS - 0091-6749 (Linking) VI - 149 IP - 4 DP - 2022 Apr TI - Development and validation of the Exercise-Induced Laryngeal Obstruction Dyspnea Index (EILODI). PG - 1437-1444 LID - S0091-6749(21)01512-8 [pii] LID - 10.1016/j.jaci.2021.09.027 [doi] AB - BACKGROUND: Exercise-induced laryngeal obstruction (EILO) causes exertional dyspnea and is important for its effect on quality of life, diagnostic confusion with exercise-induced asthma, and health care resource utilization. There is no validated patient-reported outcome measure specific to EILO. OBJECTIVE: We sought to develop, validate, and define a minimal clinically important difference for a patient-reported outcome measure to be used with adolescents and young adults with EILO. METHODS: A multidisciplinary group created a preliminary measure, modified by a 10-member participant focus group, with 20 items scored along a 5-point Likert scale. A subsequent cohort of participants recruited from a clinic, aged 12 to 21 years, with confirmed EILO by continuous laryngoscopy during exercise testing (1) completed the measure at 3 points in time over 28 days and (2) provided anchoring data in the form of a daily exercise log and categorical self-assessments of clinical improvement. Thirty additional participants without exertional dyspnea served as controls. RESULTS: Two hundred nineteen subjects with mild to severe EILO participated in the exploratory factor analysis, which identified 7 factors within the preliminary outcome measure. After a process of item reduction, a 12-item metric with a total score ranging from 0 to 48 was developed. Mean scores of patients with EILO and healthy controls at baseline were 28.8 +/- 7.4 and 4.5 +/- 7.4, respectively. A minimal clinically important difference of 6 was determined by comparison of index change with changes in categorical self-assessments of improvement. CONCLUSIONS: This is the first patient-reported outcome measure specifically designed for adolescents and young adults with EILO. CI - Copyright (c) 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. FAU - Olin, James Tod AU - Olin JT AD - Department of Pediatrics, National Jewish Health, Denver, Colo; Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: olint@njhealth.org. FAU - Shaffer, Monica AU - Shaffer M AD - Department of Rehabilitation Medicine, National Jewish Health, Denver, Colo. FAU - Nauman, Emily AU - Nauman E AD - Department of Rehabilitation Medicine, National Jewish Health, Denver, Colo. FAU - Durso, Catherine S AU - Durso CS AD - Department of Computer Science, University of Denver, Denver, Colo. FAU - Fan, Elizabeth M AU - Fan EM AD - Department of Pediatrics, National Jewish Health, Denver, Colo. FAU - Staudenmayer, Herman AU - Staudenmayer H AD - Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colo. FAU - Christopher, Kent L AU - Christopher KL AD - Department of Medicine, University of Colorado School of Medicine, Aurora, Colo. FAU - Gartner-Schmidt, Jackie AU - Gartner-Schmidt J AD - Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pa. LA - eng PT - Journal Article DEP - 20211004 PL - United States TA - J Allergy Clin Immunol JT - The Journal of allergy and clinical immunology JID - 1275002 SB - IM CIN - J Allergy Clin Immunol. 2022 Apr;149(4):1216-1217. PMID: 34953793 MH - Adolescent MH - *Airway Obstruction/diagnosis/etiology MH - *Asthma, Exercise-Induced/diagnosis MH - Dyspnea/diagnosis/etiology MH - Exercise MH - Humans MH - *Laryngeal Diseases MH - Quality of Life MH - Young Adult OTO - NOTNLM OT - CLE OT - EILO OT - EILODI OT - Exercise-Induced Laryngeal Obstruction Dyspnea Index OT - Exercise-induced laryngeal obstruction OT - VCD OT - continuous laryngoscopy during exercise OT - paradoxical vocal fold motion OT - patient-reported outcome measure OT - questionnaire OT - vocal cord dysfunction EDAT- 2021/10/08 06:00 MHDA- 2022/04/13 06:00 CRDT- 2021/10/07 20:16 PHST- 2021/03/23 00:00 [received] PHST- 2021/09/06 00:00 [revised] PHST- 2021/09/23 00:00 [accepted] PHST- 2021/10/08 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2021/10/07 20:16 [entrez] AID - S0091-6749(21)01512-8 [pii] AID - 10.1016/j.jaci.2021.09.027 [doi] PST - ppublish SO - J Allergy Clin Immunol. 2022 Apr;149(4):1437-1444. doi: 10.1016/j.jaci.2021.09.027. Epub 2021 Oct 4.